{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:24:00Z","timestamp":1792225440782,"version":"4.4.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031624","name":"Albert Schweitzer Ziekenhuis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","award":["848101002"],"award-info":[{"award-number":["848101002"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jmdjournal.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jmoldx.2024.11.003","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T04:29:59Z","timestamp":1732854599000},"page":"109-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["BCR::ABL1 Deep Molecular Response Quantification and Transcript Type Identification in Chronic Myeloid Leukemia Using a US Food and Drug Administration\u2013Approved Droplet-Based Digital PCR Assay"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6198-7035","authenticated-orcid":false,"given":"Camille","family":"Kockerols","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8857-9461","authenticated-orcid":false,"given":"Peter J.M.","family":"Valk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Hogenbirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Westerweel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2024.11.003_bib1","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib2","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib3","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib4","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib5","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/bjh.16408","article-title":"Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years","volume":"189","author":"Dulucq","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamaoncol.2020.5774","article-title":"Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial","volume":"7","author":"Atallah","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib7","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3324\/haematol.2018.194894","article-title":"Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan","volume":"103","author":"Takahashi","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12185-017-2334-x","article-title":"Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study","volume":"107","author":"Takahashi","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib9","doi-asserted-by":"crossref","first-page":"e496","DOI":"10.1097\/HS9.0000000000000496","article-title":"Digital PCR for BCR-ABL1 quantification in CML: current applications in clinical practice","volume":"4","author":"Kockerols","year":"2020","journal-title":"Hemasphere"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib10","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","article-title":"Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study","volume":"90","author":"Mori","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib11","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2015.139899","article-title":"Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study","volume":"101","author":"Lee","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib12","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-18-3373","article-title":"Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients","volume":"25","author":"Nicolini","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib13","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/cam4.2087","article-title":"Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation","volume":"8","author":"Bernardi","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib14","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bjh.18277","article-title":"Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission","volume":"198","author":"Lu","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib15","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/hon.2650","article-title":"Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome","volume":"37","author":"Colafigli","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib16","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/ajh.27359","article-title":"BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: an individual participant data meta-analysis","volume":"99","author":"Kockerols","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib17","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/clinchem\/hvaa125","article-title":"The digital MIQE guidelines update: minimum information for publication of quantitative digital PCR experiments for 2020","volume":"66","author":"Whale","year":"2020","journal-title":"Clin Chem"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib18","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib19","article-title":"Digital PCR can provide improved BCR-ABL1 detection in chronic myeloid leukemia patients in deep molecular response and sensitivity of standard quantitative methods using EAC assays","volume":"25","author":"Smitalova","year":"2021","journal-title":"Pract Lab Med"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265278","article-title":"Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia","volume":"17","author":"Shelton","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib21","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2019-125551","article-title":"A comparison of two standardized quantitative RT-PCRs with CE IVD kit for digital PCR in CML patients with different level of BCR-ABL1 transcripts","volume":"134","author":"Folta","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib22","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/s41375-022-01612-2","article-title":"Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy","volume":"36","author":"Salmon","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/ejh.13238","article-title":"Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay","volume":"103","author":"Kjaer","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1373\/clinchem.2014.221366","article-title":"Considerations for digital PCR as an accurate molecular diagnostic tool","volume":"61","author":"Huggett","year":"2015","journal-title":"Clin Chem"},{"key":"10.1016\/j.jmoldx.2024.11.003_bib25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/2472630317705680","article-title":"Digital assays part I: partitioning statistics and digital PCR","volume":"22","author":"Basu","year":"2017","journal-title":"SLAS Technol"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157824002812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157824002812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T23:04:00Z","timestamp":1740611040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157824002812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1525157824002812"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2024.11.003","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCR::ABL1 Deep Molecular Response Quantification and Transcript Type Identification in Chronic Myeloid Leukemia Using a US Food and Drug Administration\u2013Approved Droplet-Based Digital PCR Assay","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2024.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}